

| Litigation | Reference Product | Biosimilar | Filing Date | Complaint Type | Status |
|--|---------------------------|---|-------------|----------------------|---------------------------------|
| <i>AbbVie v. Amgen</i> 1:16-cv-00666 (D. Del.) | Humira® (adalimumab) | Amjevita™ (adalimumab-atto) Approved 9/23/2016 Launched 1/31/2023 | 8/4/2016 | Infringement | Settled 9/28/2017 |
| <i>AbbVie v. Boehringer Ingelheim</i> 1:17-cv-01065 (D. Del.) | Humira® (adalimumab) | Cyltezo® (adalimumab-adbm) Approved 8/25/2017, Interchangeable 10/15/2021 Launched 7/1/2023 | 8/2/2017 | Infringement | Settled 5/15/2019 |
| <i>AbbVie v. Sandoz</i> 3:18-cv-12668 (D.N.J.) | Humira® (adalimumab) | Hyrimoz™ (adalimumab-adaz) Approved 10/30/2018 Launched 7/1/2023 | 8/10/2018 | Infringement | Settled 10/16/2018 |
| <i>Coherus v. Amgen</i> 1:19-cv-00139 (D. Del.) | Biosimilar- Biosimilar | Yusimry™ (adalimumab-aqvh) Approved 12/17/2021 Launched 7/3/2023 Amjevita™ (adalimumab-atto) Approved 9/23/2016 Launched 1/31/2023 | 1/24/2019 | Infringement | Settled 11/26/2019 |
| <i>AbbVie v. Alvotech</i> 1:21-cv-02258 (N.D. Ill.) | Humira® (adalimumab) | Simlandi® (adalimumab-ryvk) Approved (Interchangeable) 2/23/2024 Launched 5/21/2024 | 4/27/2021 | Infringement | Settled 3/9/2022 |
| <i>Alvotech v. AbbVie</i> 1:21-cv-05645 (N.D. Ill.) | Humira® (adalimumab) | Simlandi® (adalimumab-ryvk) Approved (Interchangeable) 2/23/2024 Launched 5/21/2024 | 5/11/2021 | Declaratory Judgment | Voluntarily dismissed 11/5/2021 |

| Litigation | Reference Product | Biosimilar | Filing Date | Complaint Type | Status |
|--|-------------------------|---|-------------|----------------|---|
| <i>AbbVie v. Alvotech</i> 1:21-cv-02899 (N.D. Ill.) | Humira® (adalimumab) | Simlandi® (adalimumab-ryvk) Approved (Interchangeable) 2/23/2024 Launched 5/21/2024 | 5/28/2021 | Infringement | Settled 3/9/2022 |
| <i>Regeneron v. Mylan</i> 1:22-cv-00061 (N.D.W. Va.) / MDL 1:24-md-03103 (N.D.W. Va.) Fed. Cir. 24-1402, 24-1405; 24- 2002 | Eylea® (aflibercept) | Yesafili™ (aflibercept-jbvf) Approved (Interchangeable) 5/20/2024 | 8/2/2022 | Infringement | Judgment 12/27/2023- Claims 4, 7, 9, 11, and 14-17 of U.S. Patent No. 11,084,865 valid and infringed, and claims 6 and 25 of U.S. Patent No. 11,253,572 patent and claims 11 and 19 of U.S. Patent No. 10,888,601 infringed, but invalid as obvious. 3/8/2024- Summary judgment of noninfringement due to disclaimer of U.S. Patent Nos. 10,406,226, 10,464,992, and 10,857,205 Appeal 24-1402 and Cross Appeal 24-1405- Dismissed for lack of jurisdiction (all claims have not yet been decided by District Court) 6/11/2024- Permanent injunction granted Appeal 24-2002 (permanent injunction)- Ongoing |
| <i>Regeneron v. Celltrion</i> 1:23-cv-00089 (N.D.W. Va.) / MDL 1:24-md-03103 (N.D.W. Va.) Fed. Cir. 24-2058, 24-2147 | Eylea® (aflibercept) | CT-P42 (aflibercept) aBLA Pending | 11/8/2023 | Infringement | Ongoing; 6/28/2024- Preliminary injunction granted Appeals (preliminary injunction)- Ongoing |
| <i>Regeneron v. Samsung Bioepis</i> 1:23-cv-00094 (N.D.W. Va.) / MDL 1:24-md-03103 (N.D.W. Va.) Fed. Cir. 24-1966, 24-2083 | Eylea® (aflibercept) | Opuviz™ (aflibercept-yszy) Approved (Interchangeable) 5/20/2024 | 11/21/2023 | Infringement | Ongoing; 6/14/2024- Preliminary injunction granted Appeals (preliminary injunction)- Ongoing |
| <i>Regeneron v. Formycon</i> 1:23-cv-00097 (N.D.W. Va.) / MDL 1:24-md-03103 (N.D.W. Va.) Fed. Cir. 24-2009, 24-2156 | Eylea® (aflibercept) | Ahzantive® (aflibercept-mrbb) Approved 6/28/2024 | 11/29/2023 | Infringement | Ongoing; 6/21/2024- Preliminary injunction granted Appeals (preliminary injunction)- Ongoing |

| Litigation | Reference Product | Biosimilar | Filing Date | Complaint Type | Status |
|---|---------------------------|--|-------------|---|--|
| <i>Regeneron v. Samsung Bioepis</i> 1:23-cv-00106 (N.D.W. Va.) / MDL 1:24-md-03103 (N.D.W. Va.) Fed. Cir. 24-1965, 24-2082 | Eylea® (afibercept) | Opuviz™ (afibercept-yszy) Approved (Interchangeable) 5/20/2024 | 12/27/2023 | Infringement | Ongoing; 6/14/2024- Preliminary injunction granted Appeals (preliminary injunction)- Ongoing |
| <i>Regeneron v. Amgen</i> 1:24-cv-00039 (N.D.W. Va.) (Transferred from 1:24-cv-00264 (C.D. Cal.)) / MDL 1:24-md-03103 (N.D.W. Va.) Fed. Cir. 24-2351 | Eylea® (afibercept) | Pavblu™ (afibercept- ayyh) Approved 8/23/2024 Launched 10/2024 | 1/10/2024 | Infringement | Ongoing; 9/23/2024- Preliminary injunction denied Appeal (preliminary injunction)- Ongoing; 9/25/2024- Temporary injunction granted; 10/22/2024- Preliminary injunction pending appeal denied, temporary injunction lifted |
| <i>Regeneron v. Celltrion</i> 1:24-cv-00053 (N.D.W. Va.) / MDL 1:24-md-03103 (N.D.W. Va.) | Eylea® (afibercept) | CT-P42 (afibercept) aBLA Pending | 5/17/2024 | Infringement | Ongoing |
| <i>Regeneron v. Sandoz</i> 2:24-cv-08760 (D.N.J.) | Eylea® (afibercept) | Enzeevu™ (afibercept-abzv) Approved 8/9/2024 (Provisionally Interchangeable) | 8/26/2024 | Infringement | Ongoing |
| <i>Genentech v. Amgen</i> 1:17-cv-00165 (D. Del.) | Avastin® (bevacizumab) | Mvasi® (bevacizumab-awwb) Approved 9/14/2017 Launched 7/2019 | 2/15/2017 | Declaratory judgment (failure to comply with BPCIA) | Dismissed 3/1/2017- Patent dance not mandatory |
| <i>Amgen v. Genentech</i> 2:17-cv-07349 (C.D. Cal.) | Avastin® (bevacizumab) | Mvasi® (bevacizumab-awwb) Approved 9/14/2017 Launched 7/2019 | 10/6/2017 | Declaratory judgment | Dismissed 2/2/2018- Declaratory judgment not available to biosimilar |
| <i>Genentech v. Amgen</i> 1:17-cv-01407 (D. Del.) | Avastin® (bevacizumab) | Mvasi® (bevacizumab-awwb) Approved 9/14/2017 Launched 7/2019 | 10/6/2017 | Infringement | Settled 7/7/2020 |

| Litigation | Reference Product | Biosimilar | Filing Date | Complaint Type | Status |
|---|---------------------------------|---|-------------|----------------|--|
| <i>Genentech v. Amgen</i> 1:17-cv-01471 (D. Del.) | Avastin® (bevacizumab) | Mvasi® (bevacizumab-awwb) Approved 9/14/2017 Launched 7/2019 | 10/18/2017 | Infringement | Consolidated with 1:17-cv-01407 (D. Del.); Settled 7/7/2020 |
| <i>Genentech v. Immunex</i> 1:19-cv-00602 (D. Del.) Fed. Cir. 19-2155 | Avastin® (bevacizumab) | Mvasi® (bevacizumab-awwb) Approved 9/14/2017 Launched 7/2019 | 3/29/2019 | Infringement | District Court- Temporary Restraining Order and Motion to Enforce Statutory Prohibition on Commercial Marketing denied 7/18/2019; Settled 7/7/2020 Appeal (TRO and Commercial Marketing)- Affirmed 7/6/2020 |
| <i>Genentech v. Pfizer</i> 1:19-cv-00638 (D. Del.) | Avastin® (bevacizumab) | Zirabev® (bevacizumab-bvzr) Approved 6/27/2019 Launched 12/2019 | 4/5/2019 | Infringement | Settled 9/20/2019 |
| <i>Genentech v. Samsung Bioepis</i> 1:20-cv-00859 (D. Del.) | Avastin® (bevacizumab) | SB8 (bevacizumab) aBLA Pending | 6/28/2020 | Infringement | Settled 9/8/2022 |
| <i>Genentech v. Centus</i> 2:20-cv-00361 (E.D. Tex.) | Avastin® (bevacizumab) | FKB238 (bevacizumab) aBLA Pending | 11/12/2020 | Infringement | Settled 7/2/2021 |
| <i>Amgen v. Sandoz</i> 1:23-cv-02406 (D.N.J.) | Prolia® / Xgeva® (denosumab) | Jubbonti® / Wyost® (denosumab-bbdz) Approved (Interchangeable) 3/5/2024 | 5/1/2023 | Infringement | Stipulated dismissal and entry of injunction until 2/19/2025, agreement that U.S. Patent No. 7,364,736 is valid and infringed- 4/29/2024 |
| <i>Amgen v. Celltrion</i> 1:24-cv-06497 (D.N.J.) | Prolia® / Xgeva® (denosumab) | CT-P41 (denosumab) aBLA Pending | 5/28/2024 | Infringement | Settled 1/23/2025 |
| <i>Amgen v. Samsung Bioepis</i> 1:24-cv-08417 (D.N.J.) | Prolia® / Xgeva® (denosumab) | SB16 (denosumab) aBLA Pending | 8/12/2024 | Infringement | Ongoing |

| Litigation | Reference Product | Biosimilar | Filing Date | Complaint Type | Status |
|--|---|--|-------------|---|--|
| <i>Amgen v. Accord</i> 5:24-cv-00642 (E.D.N.C.) | Prolia® / Xgeva® (denosumab) | INTP23 (denosumab) aBLA Pending | 11/13/2024 | Infringement | Ongoing |
| <i>Amgen v. Fresenius Kabi</i> 1:24-cv-09555 (N.D. Ill.) | Prolia® / Xgeva® (denosumab) | FKS518 (denosumab) aBLA Pending | 10/4/2024 | Infringement | Ongoing |
| <i>Alexion v. Samsung Bioepis</i> 1:24-cv-00005 (D. Del.) Fed. Cir. 24-1829 | Soliris® (eculizumab) | Epysqli® (eculizumab-aagh) Approved 7/19/2024 | 1/3/2024 | Infringement | District Court- Preliminary injunction denied 5/6/2024; Voluntarily dismissed 8/30/2024 Appeal (preliminary injunction)- Temporary injunction pending appeal denied 7/29/2024; Voluntarily dismissed 8/30/2024 |
| <i>Amgen v. Hospira</i> 1:15-cv-00839 (D. Del.) Fed. Cir. 16-2179 Fed. Cir. 19-1067 Fed. Cir. 19-1102 | Epogen® / Procrit® (epoetin alfa) | Retacrit® (epoetin alfa-epbx) Approved 5/15/2018 Launched 11/2018 | 9/18/2015 | Infringement; Declaratory judgment (failure to comply with BPCIA) | District Court- 9/26/2017: Jury Verdict (some claims valid and infringed; some claims invalid) Appeal 16-2179 (motion to compel manufacturing information on patents not asserted)- 8/10/2017: Dismissed for lack of jurisdiction; Petition for writ of mandamus denied Appeal 19-1067 and Cross Appeal 19-1102 (final judgment)- 12/16/2019: Affirmed; 3/16/2020: Petition for en banc rehearing denied |
| <i>Sandoz v. Amgen</i> 3:13-cv-02904 (N.D. Cal.) Fed. Cir. 14-1693 | Enbrel® (etanercept) | Erelzi® (etanercept-szzs) Approved 8/30/2016 | 6/24/2013 | Declaratory Judgment | District Court- Dismissed for lack of subject matter jurisdiction 11/19/2013 Appeal- Affirmed 12/5/2014 |
| <i>Amgen v. Sandoz</i> 2:16-cv-01118 (D.N.J.) Fed. Cir. 20-1037 Sup. Ct. 20-1110 | Enbrel® (etanercept) | Erelzi® (etanercept-szzs) Approved 8/30/2016 | 2/26/2016 | Infringement | District Court- 8/9/2019: '182 patent claims 11-23 and 35-36 and '522 patent claims 3, 8, and 10 not invalid. Parties previously stipulated to infringement. Permanent injunction issued. Appeal- Affirmed 7/1/2020; Request for <i>en banc</i> rehearing denied 9/29/2020 Supreme Court- Certiorari denied 5/17/2021 |

| Litigation | Reference Product | Biosimilar | Filing Date | Complaint Type | Status |
|---|---------------------------|---|-------------|--|--|
| <i>Amgen v. Samsung Bioepis</i> 2:19-cv-11755 (D.N.J.) | Enbrel® (etanercept) | Eticovo™ (etanercept-ykro) Approved 4/25/2019 | 4/30/2019 | Infringement | 11/3/2021- Final judgment in favor of Amgen, Permanent injunction issued (will terminate when U.S. Patent Nos. 8,063,182 and 8,163,522 expire on April 24, 2029) |
| <i>Amgen v. Sandoz</i> 3:14-cv-04741 (N.D. Ca.) Fed. Cir. 15-1499 S. Ct. 15-1039 S. Ct. 15-1195 Fed. Cir. 18-1551 | Neupogen® (filgrastim) | Zarxio® (filgrastim-sndz) Approved 3/6/2015 Launched 9/2015 | 10/24/2014 | Infringement; BPCIA Interpretation | BPCIA Interpretation: District Court- 3/19/2015: Patent dance not mandatory, 180-day notice can be given before FDA approval Appeal 15-1499- 7/21/2015: Affirmed patent dance not mandatory, but 180-day notice cannot be given before FDA approval. S. Ct. Appeals 15-1039 and 15-1195- 6/12/2017: Agreed with District Court that 180-day notice can be given before FDA approval, no injunction available under federal law to force compliance with patent dance; remanded to determine whether state law provided injunction Appeal 15-1499 (on remand from S. Ct.)- 12/14/2017: State law did not provide injunction for failure to comply with patent dance Infringement/Validity: District Court- 1/8/2018: Summary judgment of non-infringement and dismissal of invalidity counterclaims Appeal 18-1551- 5/8/2019: Affirmed summary judgment; 9/3/2019 Petition for rehearing <i>en banc</i> granted-in-part |
| <i>Amgen v. Apotex</i> 0:15-cv-62081 (S.D. Fla.) Fed. Cir. 17-1010 | Neupogen® (filgrastim) | Grastofil™ (filgrastim) aBLA Pending | 10/2/2015 | Infringement | Consolidated with 0:15-cv-61631 (S.D. Fla.) District Court- 9/6/2016: Patent not infringed, not unenforceable, and counterclaims of invalidity dismissed Appeal- Affirmed 11/13/2017 |
| <i>Amgen v. Adello</i> 2:18-cv-03347 (D.N.J.) | Neupogen® (filgrastim) | Releuko™ (filgrastim-ayow) Approved 2/25/2022 Launched 11/2022 | 3/8/2018 | Infringement | Settled 11/25/2019 |
| <i>Amgen v. Pfizer</i> 1:18-cv-01064 (D. Del.) | Neupogen® (filgrastim) | Nivestym® (filgrastim-aafi) Approved 7/20/2018 Launched 10/2018 | 7/18/2018 | Infringement | Settled 9/8/2021 |

| Litigation | Reference Product | Biosimilar | Filing Date | Complaint Type | Status |
|---|---|--|-------------|--|--|
| <i>Amgen v. Tanvex</i> 3:19-cv-01374 (S.D. Cal.) | Neupogen® (filgrastim) | Nypozi™ (filgrastim-txid) Approved 6/28/2024 | 7/23/2019 | Infringement | Settled 12/20/2019 |
| <i>Amgen v. Pfizer</i> 1:20-cv-00561 (D. Del.) | Neupogen® (filgrastim) | Nivestym® (filgrastim-aafi) Approved 7/20/2018 Launched 10/2018 | 4/24/2020 | Infringement | Settled 9/8/2021 |
| <i>Amgen v. Apotex</i> 0:18-cv-61828 (S.D. Fla.) | Neupogen® (filgrastim) / Neulasta® (pegfilgrastim) | Grastofil™ (filgrastim) aBLA Pending Lapelga™ (pegfilgrastim) aBLA Pending | 8/7/2018 | Infringement | Settled 11/15/2019 |
| <i>Sandoz v. Amgen</i> 3:19-cv-00977 (N.D. Cal.) | Neupogen® (filgrastim) / Neulasta® (pegfilgrastim) | Zarxio® (filgrastim-sndz) Approved 3/6/2015 Launched 9/2015 Ziextenzo® (pegfilgrastim-bmez) Approved 11/4/2019 Launched 11/2019 | 2/21/2019 | Declaratory judgment | Related to 3:14-cv-04741 (N.D. Cal.) and 3:16-cv-02581 (N.D. Cal.) Voluntarily dismissed 5/13/2019 |
| <i>Amgen v. Apotex</i> 0:15-cv-61631 (S.D. Fla.) Fed. Cir. 16-1308 S. Ct. 16-332 Fed. Cir. 17-1010 | Neulasta® (pegfilgrastim) | Lapelga™ (pegfilgrastim) aBLA Pending | 8/6/2015 | Infringement | Preliminary Injunction District Court- 12/9/2015: Granted preliminary injunction preventing launch until 180 days after post-licensure notice of commercial marketing Appeal 16-1308- Affirmed 7/5/2016 S. Ct.- Cert denied 12/12/2016 Infringement/Validity: District Court- 9/6/2016: Not infringed, not unenforceable, invalidity dismissed Appeal 17-1010- Affirmed 11/13/2017 |
| <i>Amgen v. Sandoz</i> 2:16-cv-01276 (D.N.J.) | Neulasta® (pegfilgrastim) | Ziextenzo® (pegfilgrastim-bmez) Approved 11/4/2019 Launched 11/2019 | 3/4/2016 | Declaratory judgment (BPCIA non-compliance) | Dismissed 3/31/2017 |

| Litigation | Reference Product | Biosimilar | Filing Date | Complaint Type | Status |
|---|------------------------------|--|-------------|---|--|
| <i>Amgen v. Sandoz</i> 3:16-cv-02581 (N.D. Cal.) Fed. Cir. 18-1552 | Neulasta® (pegfilgrastim) | Ziextenzo® (pegfilgrastim-bmez) Approved 11/4/2019 Launched 11/2019 | 5/12/2016 | Infringement | District Court- Summary judgment of non-infringement 12/19/2017 Appeal (consolidated with 18-1551)- Affirmed 5/8/2019 |
| <i>Amgen v. Coherus</i> 1:17-cv-00546 (D. Del.) Fed. Cir. 18-1993 | Neulasta® (pegfilgrastim) | Udenyca® (pegfilgrastim-cbqv) Approved 11/2/2018 Launched 1/2019 | 5/10/2017 | Infringement | District Court- Dismissed for failure to state a claim 4/18/2018 Appeal- Affirmed 7/29/2019 |
| <i>Amgen v. Mylan</i> 2:17-cv-01235 (W.D. Pa.) | Neulasta® (pegfilgrastim) | Fulphila® (pegfilgrastim-jmdb) Approved 6/4/2018 Launched 7/2018 | 9/22/2017 | Infringement | Terminated 9/16/2019- Stipulation of non-infringement |
| <i>Amgen v. Hospira</i> 1:20-cv-00201 (D. Del.) | Neulasta® (pegfilgrastim) | Nyvepria® (pegfilgrastim-apgf) Approved 6/10/2020 Launched 1/2021 | 2/11/2020 | Infringement | Settled 3/21/2022 |
| <i>Celltrion v. Janssen</i> 1:14-cv-11613 (D. Mass.) | Remicade® (infliximab) | Inflectra® (infliximab-dyyb) Approved 4/5/2016 Launched 11/2016 | 3/31/2014 | Declaratory judgment (prior to aBLA filing) | Voluntarily dismissed 10/23/2014 (Biosimilar called Remsima® in complaint, but has since been named Inflectra® in the US) |
| <i>Celltrion v. The Kennedy Trust for Rheumatology Research</i> 1:14-cv-02256 (S.D.N.Y.) | Remicade® (infliximab) | Inflectra® (infliximab-dyyb) Approved 4/5/2016 Launched 11/2016 | 3/31/2014 | Declaratory judgment (prior to aBLA filing) | Dismissed for lack of subject matter jurisdiction 12/1/2014 |
| <i>Hospira v. Janssen</i> 1:14-cv-07049 (S.D.N.Y.) | Remicade® (infliximab) | Inflectra® (infliximab-dyyb) Approved 4/5/2016 Launched 11/2016 | 8/29/2014 | Declaratory judgment (prior to aBLA filing) | Dismissed for lack of subject matter jurisdiction 12/1/2014 |

| Litigation | Reference Product | Biosimilar | Filing Date | Complaint Type | Status |
|---|----------------------------|---|-------------|----------------|--|
| <i>Janssen v. Celltrion</i> 1:15-cv-10698 (D. Mass.) Fed. Cir. 17-1120 | Remicade® (infliximab) | Inflectra® (infliximab-dyyb) Approved 4/5/2016 Launched 11/2016 | 3/6/2015 | Infringement | District Court- Partial judgment 9/26/2016 finding '471 patent claims invalid for obviousness-type double patenting; Stipulated dismissals on remaining patents Appeal (double patenting)- 1/23/2018: Dismissed as moot because reexam appeal 17-1257 affirmed claims were unpatentable |
| <i>Janssen v. Celltrion</i> 1:16-cv-11117 (D. Mass.) | Remicade® (infliximab) | Inflectra® (infliximab-dyyb) Approved 4/5/2016 Launched 11/2016 | 6/14/2016 | Infringement | Dismissed 8/7/2017. Infringement issues will be litigated in 1:17-cv-11008 (D. Mass.) |
| <i>Janssen v. Samsung Bioepis</i> 2:17-cv-03524 (D.N.J.) | Remicade® (infliximab) | Renflexis® (infliximab-abda) Approved 4/21/2017 Launched 7/2017 | 5/17/2017 | Infringement | Stipulated dismissal 11/30/2017 |
| <i>Janssen v. Celltrion</i> 1:17-cv-11008 (D. Mass.) Fed. Cir. 18-2321 Fed. Cir. 18-2350 | Remicade® (infliximab) | Inflectra® (infliximab-dyyb) Approved 4/5/2016 Launched 11/2016 | 5/31/2017 | Infringement | District Court- Summary judgment of non-infringement 7/31/2018 Appeal 18-2321 and Cross-Appeal 18-2350- Affirmed 3/5/2020 |
| <i>Sanofi-Aventis v. Eli Lilly</i> 1:14-cv-00113 (D. Del.) | Lantus® (insulin glargine) | Basaglar® (insulin glargine) Approved 12/16/2015 Launched 12/2016 | 1/30/2014 | Infringement | Settled 9/28/2015 |
| <i>Sanofi-Aventis v. Eli Lilly</i> 1:14-cv-00884 (D. Del.) | Lantus® (insulin glargine) | Basaglar® (insulin glargine) Approved 12/16/2015 Launched 12/2016 | 7/7/2014 | Infringement | Settled 5/8/2015 |
| <i>Sanofi-Aventis v. Merck</i> 1:16-cv-00812 (D. Del.) | Lantus® (insulin glargine) | Lusduna™ Nexvue™ (insulin glargine) Tentative Approval 7/20/2017 | 9/16/2016 | Infringement | Dismissed 10/29/2018 – Merck no longer pursuing product |

| Litigation | Reference Product | Biosimilar | Filing Date | Complaint Type | Status |
|---|----------------------------|---|-------------|----------------------|--|
| <i>Sanofi-Aventis v. Merck</i> 2:17-cv-05914 (D.N.J.) | Lantus® (insulin glargine) | Lusduna™ Nexvue™ (insulin glargine) Tentative Approval 7/20/2017 | 8/8/2017 | Infringement | Dismissed 11/13/2018 – Merck no longer pursuing product |
| <i>Sanofi-Aventis v. Mylan</i> 2:17-cv-09105 (D.N.J.) Fed. Cir. 21-1262 | Lantus® (insulin glargine) | Semglee® (insulin glargine-yfng) Approved 6/11/2020, Launched 8/2020; Interch. Approved 7/28/2021, Launched 11/2021 | 10/24/2017 | Infringement | District Court- 3/9/2020: Claims 21, 22, 25 and 30 of '844 patent not infringed, and invalid for lack of written description Appeal- Dismissed as moot 12/29/2021 |
| <i>Biogen v. Sandoz</i> 1:22-cv-01190 (D. Del.) | Tysabri® (natalizumab) | Tyruko® (natalizumab-sztn) Approved 8/24/2023 | 9/9/2022 | Infringement | Ongoing, Preliminary injunction denied 6/20/2023 |
| <i>Genentech v. Sandoz</i> 1:17-cv-13507 (D.N.J.) | Rituxan® (rituximab) | Rixathon® (rituximab) aBLA Pending | 12/21/2017 | Infringement | Stipulated dismissal 12/6/2018. Sandoz no longer pursuing its biosimilar application. |
| <i>Celltrion v. Genentech</i> 4:18-cv-00276 (N.D. Cal.) Fed. Cir. 18-2161 | Rituxan® (rituximab) | Truxima® (rituximab-abbs) Approved 11/28/2018 Launched 11/2019 | 1/1/2018 | Declaratory judgment | District Court- Dismissed for failure to state a claim 5/10/2018 Appeal voluntarily dismissed 11/30/2018 |
| <i>Genentech v. Celltrion</i> 1:18-cv-00574 (D.N.J.) | Rituxan® (rituximab) | Truxima® (rituximab-abbs) Approved 11/28/2018 Launched 11/2019 | 1/12/2018 | Infringement | Settled 11/1/2018 |
| <i>Genentech v. Celltrion</i> 1:18-cv-11553 (D.N.J.) | Rituxan® (rituximab) | Truxima® (rituximab-abbs) Approved 11/28/2018 Launched 11/2019 | 7/11/2018 | Infringement | Related to 1:18-cv-00574 (D.N.J.) Settled 11/1/2018 |
| <i>Genentech v. Dr. Reddy's</i> 1:23-cv-22485 (D.N.J.) | Rituxan® (rituximab) | DRL_RI (rituximab) aBLA Pending | 11/17/2023 | Infringement | Settled 4/9/2024 |

| Litigation | Reference Product | Biosimilar | Filing Date | Complaint Type | Status |
|---|-----------------------------|---|-------------|----------------------|---|
| <i>Genentech v. Biogen</i> 1:23-cv-11573 (D. Del.) | Actemra® (tocilizumab) | Tofidence™ (tocilizumab-bavi) Approved 9/29/2023 | 7/13/2023 | Infringement | Settled 10/23/2023 |
| <i>Genentech v. Pfizer</i> 1:17-cv-01672 (D. Del.) | Herceptin® (trastuzumab) | Trazimera® (trastuzumab-qyyp) Approved 3/11/2019 Launched 2/2020 | 11/17/2017 | Infringement | Settled 12/4/2018 |
| <i>Celltrion v. Genentech</i> 4:18-cv-00274 (N.D. Cal.) Fed. Cir. 18-2160 | Herceptin® (trastuzumab) | Herzuma® (trastuzumab-pkrb) Approved 12/14/2018 Launched 3/2020 | 1/11/2018 | Declaratory judgment | District Court- Dismissed for failure to state a claim 5/10/2018 Appeal- Voluntarily dismissed 11/30/2018 |
| <i>Genentech v. Celltrion</i> 1:18-cv-00095 (D. Del.) | Herceptin® (trastuzumab) | Herzuma® (trastuzumab-pkrb) Approved 12/14/2018 Launched 3/2020 | 1/12/2018 | Infringement | Settled 12/27/2018 |
| <i>Genentech v. Amgen</i> 1:18-cv-00924 (D. Del.) Fed. Cir. 19-2156 | Herceptin® (trastuzumab) | Kanjinti® (trastuzumab-anns) Approved 6/13/2019 Launched 7/2019 | 6/21/2018 | Infringement | District Court- Temporary Restraining Order and Preliminary Injunction denied 7/18/2019; Settled 7/7/2020 Appeal (TRO and PI)- Affirmed 3/6/2020 |
| <i>Genentech v. Celltrion</i> 1:18-cv-01025 (D. Del.) | Herceptin® (trastuzumab) | Herzuma® (trastuzumab-pkrb) Approved 12/14/2018 Launched 3/2020 | 7/11/2018 | Infringement | Consolidated with 1:18-cv-00095 (D. Del.), Settled 12/27/2018 |
| <i>Genentech v. Samsung Bioepis</i> 1:18-cv-01363 (D. Del.) | Herceptin® (trastuzumab) | Ontruzant® (trastuzumab-dttb) Approved 1/18/2019 Launched 4/2020 | 9/4/2018 | Infringement | Settled 7/1/2019 |
| <i>Genentech v. Tanvex</i> 3:22-cv-00809 (S.D. Cal.) | Herceptin® (trastuzumab) | TX-05 (trastuzumab) aBLA pending | 6/2/2022 | Infringement | Settled 2/10/2023 |

| Litigation | Reference Product | Biosimilar | Filing Date | Complaint Type | Status |
|--|---------------------------|--|-------------|----------------|-------------------|
| <i>Janssen v. Amgen</i> 1:22-cv-01549 (D. Del.) | Stelara® (ustekinumab) | Wezlana™ (ustekinumab-auub) Approved (Interchangeable) 10/31/2023 Launched 1/2025 | 11/29/2022 | Infringement | Settled 5/23/2023 |